Peer-influenced content. Sources you trust. No registration required. This is HCN.

Psychiatrist.comLong-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia

The authors concluded that, after reviewing the 13-year-study, “switching to LAIs during the first 3 years of treatment improved antipsychotic adherence, decreased relapses, and reduced long-term mortality.” With few studies available comparing the long-term effectiveness between patients who switched to LAIs and those who remained on oral antipsychotics (OAPs), they hope the evidence presented supports the benefits of early LAI treatment in schizophrenia.